A recent trial has linked Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM) to significantly lower blood sugar levels than fingerstick testing.
The study, published in The New England Journal of Medicine and run by UK hospitals, tested if CGMs benefit people with Type 1 diabetes and high blood glucose levels. It found that patients who used FreeStyle Libre for 24 weeks experienced a mean 0.8 percentage point decline in their blood glucose level and spent 130 minutes longer in their target range each day and 43 minutes less per day with low blood sugar.
The study also evaluated patient satisfaction with diabetes treatment and glucose monitoring. Patients using FreeStyle Libre scored higher on the Diabetes Treatment Satisfaction Questionnaire and Glucose Monitoring Satisfaction Survey, indicating greater overall satisfaction with Abbott’s CGM than with fingerstick testing. The researchers are now evaluating whether the CGM system as cost effective.
To read more, CLICK HERE.
